• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    8/26/24 6:49:57 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMLX alert in real time by email
    SC 13G 1 d866005dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Amylyx Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    03237H101

    (CUSIP Number)

    August 14, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 03237H101       13G

     

     1.   

      NAMES OF REPORTING PERSONS

     

      TCG Crossover GP II, LLC

     2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

      SEC USE ONLY

     

     4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      4,643,812 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

     0

       8.  

      SHARED DISPOSITIVE POWER

     

     4,643,812 (1)

     9.   

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,643,812 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.8% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      OO

     

    (1)

    These securities are held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 68,082,468 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024 (the “Form 10-Q”).


    CUSIP No. 03237H101       13G

     

     1.   

      NAMES OF REPORTING PERSONS

     

      TCG Crossover Fund II, L.P.

     2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

      SEC USE ONLY

     

     4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      4,643,812 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

     0

       8.  

      SHARED DISPOSITIVE POWER

     

     4,643,812 (1)

     9.   

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,643,812 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.8% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 68,082,468 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 03237H101       13G

     

     1.   

      NAMES OF REPORTING PERSONS

     

      Chen Yu

     2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

      SEC USE ONLY

     

     4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

      SOLE VOTING POWER

     

      0

       6.  

      SHARED VOTING POWER

     

      4,643,812 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

     0

       8.  

      SHARED DISPOSITIVE POWER

     

     4,643,812 (1)

     9.   

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,643,812 (1)

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.8% (2)

    12.  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 68,082,468 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 03237H101       13G

     

    Item 1(a).

    Name of Issuer:

    Amylyx Pharmaceuticals, Inc. (the “Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    43 Thorndike St.

    Cambridge, Massachusetts 02141

     

    Item 2(a).

    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by TCG Crossover Fund II, L.P. (“TCG Crossover II”), TCG Crossover GP II, LLC (“TCG Crossover GP II” and together with TCG Crossover II, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

     

    Item 2(b)

    Address of Principal Business Office, or if None, Residence:

    The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.

     

    Item 2(c).

    Citizenship:

    TCG Crossover GP II is a limited liability company organized under the laws of the State of Delaware. TCG Crossover II is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share (“Common Stock”).

     

    Item 2(e).

    CUSIP Number:

    03237H101

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 03237H101       13G

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreement of TCG Crossover II and the limited liability company agreement of TCG Crossover GP II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 03237H101       13G

     

    Item 9.

    Notice of Dissolution of the Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11 promulgated under the Act.

    Material to be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement.


    CUSIP No. 03237H101       13G

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 26, 2024

     

    TCG Crossover Fund II, L.P.
    By:   TCG Crossover GP II, LLC
    Its:   General Partner
    By:  

    /s/ Craig Skaling

      Authorized Signatory
    TCG Crossover GP II, LLC
    By:  

    /s/ Craig Skaling

      Authorized Signatory

    /s/ Craig Skaling, as attorney-in-fact for Chen Yu

    Chen Yu

     

    Get the next $AMLX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMLX

    DatePrice TargetRatingAnalyst
    7/10/2025$10.00Buy
    Goldman
    6/24/2025$17.00Buy
    Guggenheim
    6/17/2025$12.00Buy
    Citigroup
    5/30/2025Buy
    TD Cowen
    4/7/2025$7.00Neutral → Outperform
    Mizuho
    11/18/2024$3.00 → $11.00Neutral → Outperform
    Robert W. Baird
    10/23/2024$4.20 → $10.00Neutral → Buy
    BofA Securities
    3/18/2024$32.00 → $4.00Buy → Neutral
    Mizuho
    More analyst ratings

    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Mazzariello Gina sold $246,148 worth of shares (30,000 units at $8.20), decreasing direct ownership by 16% to 156,969 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    8/14/25 4:20:11 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Fonteyne Paul R.

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    6/9/25 4:12:55 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Firestone Karen

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    6/9/25 4:08:39 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Amylyx from this offering are expected to be $175.0 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the

    9/10/25 12:06:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the public offering at the public offering price per share, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    9/9/25 4:01:00 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

    - AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24 - AMX0035 continued to be generally well-tolerated Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the decision to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with progressive supranuclear palsy (PSP). AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24. Based on these results, the Company will discontinue the Phase 2b trial and open-label extension and will not initiate the Phase 3 portion of the program

    8/27/25 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    SEC Filings

    View All

    SEC Form 8-K filed by Amylyx Pharmaceuticals Inc.

    8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    9/10/25 4:55:03 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.

    424B5 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    9/10/25 4:44:46 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.

    424B5 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    9/9/25 5:24:52 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Amylyx Pharmaceuticals with a new price target

    Goldman resumed coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    7/10/25 8:47:27 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Amylyx Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $17.00

    6/24/25 7:57:48 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Amylyx Pharmaceuticals with a new price target

    Citigroup initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/17/25 7:48:19 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 2, 2022 - FDA Roundup: September 2, 2022

    For Immediate Release: September 02, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:   On Thursday, the FDA published the FDA Voices: “Using A Whole-Of-Governments Approach to Combating Illicit Health Products,” by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office. Crimi

    9/2/22 1:46:13 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zeiher Bernhardt G bought $37,005 worth of shares (10,000 units at $3.70) (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/24/25 4:15:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Frates James M bought $101,368 worth of shares (40,000 units at $2.53), increasing direct ownership by 21% to 233,464 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    9/16/24 5:30:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Firestone Karen bought $106,590 worth of shares (50,000 units at $2.13), increasing direct ownership by 1,000% to 55,000 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    9/9/24 4:05:06 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursui

    4/8/24 6:24:09 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

    - Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer ("CMO"). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious disease

    11/28/23 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

    Amylyx will seek re-examination of its Conditional Marketing Authorisation Application Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name ALBRIOZA®, for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the European Union (EU). Today's update follows the Company's May 2023 announcement that the CHMP was trending toward a negative opinion.

    6/23/23 8:14:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Financials

    Live finance-specific insights

    View All

    Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 Cash, cash equivalents, and marketable securities of $180.8 million as of June 30, 2025; cash runway expected through the end of 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time   Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the second quarter ended June 30, 2025. "As we look ahead to the second half of the year and into 2026, we remain encouraged by the strength of our pipeline and the continued momentum towards our cl

    8/7/25 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its second quarter 2025 financial results on Thursday, August 7, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800) 836-8184 (U.S. & Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-pre

    7/31/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

    - Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation, underway in post-bariatric hypoglycemia; completion of recruitment expected in 2025, with topline data anticipated in first half of 2026 - In the Phase 2b trial, avexitide 90 mg once daily led to a 64% least-squares mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events in post-bariatric hypoglycemia, the FDA-agreed upon primary outcome that LUCIDITY is evaluating - Population pharmacokinetic and pharmacodynamic data demonstrated avexitide 90 mg once daily has sustained therapeutic exposure for 24 hours - Amylyx to host

    7/13/25 5:00:00 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amylyx Pharmaceuticals Inc.

    SC 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/12/24 1:22:53 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/4/24 10:56:42 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    10/25/24 5:38:25 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care